Physician profile
Benjamin E Kaplan
NPI 1407267099
$4,894.39
in general payments reported to CMS, 2019-2025
29 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $748 · 2021: $938 · 2022: $746 · 2023: $419 · 2024: $509 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,115.57 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,035.58 | 2019-2023 | Relistor |
| Scilex Pharmaceuticals INC. | $724.69 | 2019-2025 | Ztlido |
| Zyla Life Sciences, INC. | $346.37 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $247.76 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $171.06 | 2020-2022 | |
| Sentynl Therapeutics, INC. | $164.26 | 2019-2020 | |
| Valinor Pharma, LLC | $144.75 | 2023-2025 | Movantik |
| Pfizer INC. | $138.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $106.17 | 2019-2023 | Belsomra |
| Almatica Pharma LLC | $97.44 | 2021-2022 | |
| Redhill Biopharma INC. | $69.92 | 2021 | |
| Tonix Medicines, INC. | $67.35 | 2025 | Tonmya |
| Axonics, INC. | $66.56 | 2022 | |
| Averitas Pharma INC. | $43.91 | 2025 | Qutenza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $42.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.25 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $34.87 | 2025 | |
| Assertio Therapeutics, INC. | $31.20 | 2019-2020 | |
| Daiichi Sankyo INC. | $30.43 | 2019 | |
| Electronic Waveform Lab, INC. | $29.14 | 2019 | |
| Shionogi INC | $27.86 | 2019 | |
| Horizon Therapeutics Plc | $27.79 | 2019 | |
| Virtus Pharmaceuticals LLC | $26.84 | 2021 | |
| Pernix Therapeutics Holdings, INC. | $13.77 | 2019 | |
| Forte Bio-Pharma LLC | $13.39 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.24 | 2022 | |
| Hikma Pharmaceuticals USA | $11.84 | 2021 | |
| West Therapeutics Development, LLC | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.